menu

CME: How to Identify & Manage Patients with Progressive-Fibrosing ILD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

How to Identify & Manage Patients with Progressive-Fibrosing ILD

Program Information
Recommended
How to Identify & Manage Patients with Progressive-Fibrosing ILD
RestartResume
ILD diagnosis is complex and management can be tricky. Hear how to navigate this path and how the patient’s perspective can influence the care plan.

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This discussion highlights the challenges associated with progressive-fibrosing ILD diagnosis, explains management differences for connective tissue disease-associated ILD, and reviews therapeutic options for the management of PF-ILD.

  • Disclosure of Conflicts of Interest

    • Jeffrey J. Swigris, DO, MS has received honoraria from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech.
    • Amy L. Olson, MD, MSPH has served as a scientific advisor for Boehringer Ingelheim Pharmaceuticals, Inc. She has also served on the speakers bureau for Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech and has done contract research for Boehringer Ingelheim Pharmaceuticals, Inc.
    • Kathleen Rosen, NP has served as a scientific advisor for Medical Graphics and as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc. She has also served on the speakers bureau for Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech and has done contract research for Boehringer Ingelheim Pharmaceuticals, Inc.
  • Target Audience

    These activities are for pulmonologists, radiologists, and primary care providers, as well as other health care providers who may be involved in the management of patients with ILD.

  • Learning Objectives

    • Discuss progressive-fibrosing ILD (PF-ILD) and the challenges associated with this phenotype
    • Explain manifestations of and management differences for connective tissue disease (CTD)-associated ILD
    • Review therapeutic options for the management of PF-ILD
  • Accreditation and Credit Designation Statements

    ACCREDITATION STATEMENT
    The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    CREDIT DESIGNATION
    Physicians
    The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    The France Foundation

  • Commercial Support

    This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

  • Terms of Use

    The France Foundation (TFF) requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

  • Instructions

    METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
    Technical Requirements:http://www.francefoundation.com/general-requirements.html

    1. There are no fees for participating in and receiving credit for this activity.
    2. Review the activity objectives and CME/CE information.
    3. Complete the CME/CE activity 
    4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
    5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    6. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be emailed to you. It can also be downloaded from the Credits section of your Profile at any time.
  • Disclaimer

    The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

  • Short description

    Listen to this brief education to optimize the treatment of your patients with progressive-fibrosing ILD.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/21/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.